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Introduction: 30 day mortality in patients with Acute Respiratory Failure (ARF) is approximately 30%, defined as
patients requiring ventilator support for more than 6 hours. Novel biomarkers are needed to predict patient
outcomes and to guide potential future therapies. The activins A and B, members of the Transforming Growth
Factor β family of proteins, and their binding protein, follistatin, have recently been shown to be important
regulators of inflammation and fibrosis but no substantial data are available concerning their roles in ARF.
Our objectives were to evaluate whether the serum levels of activin A, B and follistatin are elevated in 518 patients
with ARF from the FINNALI study compared the concentrations in 138 normal subjects that form a reference range.
Methods: Specific assays for activin A, B and follistatin were used and the results analyzed according to diagnostic
groups as well as according to standard measures in intensive care. Multivariable logistic regression was used to
create a model to predict death at 90 days and 12 months from the onset of the ARF.
Results: Serum activin A and B were significantly elevated in most patients and in most of the diagnostic groups.
Patients who had activin A and/or B concentrations above the reference maximum were significantly more likely to
die in the 12 months following admission [either activin A or B above reference maximum: Positive Likelihood Ratio
[LR+] 1.65 [95% CI 1.28-2.12, P = 0.00013]; both activin A and B above reference maximum: LR + 2.78 [95% CI 1.96-
3.95, P < 0.00001]. The predictive model at 12 months had an overall accuracy of 80.2% [95% CI 76.6-83.3%].
Conclusions: The measurement of activin A and B levels in these patients with ARF would have assisted in
predicting those at greatest risk of death. Given the existing data from animal studies linking high activin A levels
to significant inflammatory challenges, the results from this study suggest that approaches to modulate activin A
and B bioactivity should be explored as potential therapeutic agents.Introduction
Managing acute respiratory failure (ARF) in the ICU is a
major challenge [1-5]. Mortality in ARF, defined as requi-
ring the need for ventilation for more than 6 hours, is
approximately 30% at 30 days after ARF onset [3,6-8], and
despite many advances in care, improved methods are
required to define those at greatest risk and to predict* Correspondence: david.de.kretser@monash.edu
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reproduction in any medium, provided the oroutcomes. Identifying novel biomarkers in ARF may lead
to potential new therapies and enable better prediction of
short and long term outcomes.
Activin A, a dimer of βA subunits, is a member of the
transforming growth factor-β [TGFβ] superfamily, and
was isolated originally for its capacity to stimulate
follicle-stimulating hormone secretion by the pituitary
gland. The amino acid sequence of the βA subunit is
100% conserved from the mouse to the human [9]. In
experimental animal models in sheep and mice, it was
subsequently shown to be a major stimulator of the
inflammatory cascade initiated by lipopolysaccharide
(LPS) [10,11] and drives inflammation and fibrosis in
various pathologies [9]. Another member of this familyral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Patient selection flowchart. The initial selection step was
the presence of an Acute Physiology and Chronic Health Evaluation
(Apache) III diagnostic group and a sample available for analysis.
Activin B samples below the limit of detection were given a nominal
value to enable further analysis. Patients with non-specific etiologies
were removed to enable examination of specific etiologies in
this study.
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sequence homology to βA [9]. These proteins are pro-
duced in multiple organs and tissues [9].
Many factors regulate activin A bioactivity but follistatin
is regarded as the major regulator, binding activin A virtu-
ally irreversibly and targeting the complex to a lysosomal
degradation pathway [12,13]. Activin A stimulates follis-
tatin production, thereby modulating its own biological
actions [9,11] and a high activin A to follistatin ratio favors
pro-inflammatory and fibrotic processes that are decrea-
sed by follistatin [14]. Administration of follistatin to mice
before they were given LPS, resulted in a markedly lower
TNFα response and altered the magnitude and temporal
secretory pattern of IL1β and IL6 [15]. Further, follistatin
administration prior to a lethal LPS injection was found to
halve the mortality in mice [15].
A recent study used the intra-tracheal administration
of an adenoviral associated vector expressing activin A
in mice and showed that it induced a profound inflam-
matory response resulting in a cytokine storm and the
transformation of normal lungs to an emphysematous
phenotype in 3 to 4 weeks in the surviving mice [16].
Activin B, a closely related member of the TGFβ-
activin protein subfamily, binds to the same receptor
and is regarded as a weak activin A agonist, but there
are very limited data concerning its actions in inflamma-
tion [9]. Its bioactivity can also be blocked by follistatin.
There are only limited data about the role of activins A
and B in humans. A small study conducted in critically ill
patients with septicemia suggested that markedly elevated
serum activin A levels were associated with an increased
risk of death [17]. In part, the absence of well-characterized
assays for activins A and B and follistatin, and normal-
range values obtained from a substantial number of volun-
teers carefully selected to exclude illnesses, particularly
those with an inflammatory component, has hindered the
acquisition of human data. Such well-defined normal
ranges are critical to using serum activin A, B and follista-
tin as sensitive markers of inflammation. Previously defined
normal ranges for activin A are inadequate due to limited
numbers of normal subjects [18,19].
This study establishes normal reference ranges for
serum activin A and B and follistatin levels, and reports
their levels in a large cohort of critically ill patients with
ARF in the FINNALI study [3]. This study also estab-
lishes that serum activin A and B levels may assist in
predicting survival outcomes of patients with ARF and
provides a rationale to explore therapeutic avenues to
modulate activin A and B.
Materials and methods
Ethics
The Board of the Finnish Quality Consortium (Intensium
Ltd, Kuopio, Finland) and the Ethics Committees of eachparticipating hospital approved the study design and use
of the quality database for the purposes of the FINNALI
study [3]. Due to the established nature of the ICU care
provided in each ICU, the ethics committees waived the
requirement for informed consent for data registration.
The normal-range study was approved by the Southern
Health Human Ethics Committee, Clayton, Victoria,
Australia.
Samples from the FINNALI Study
From the FINNALI study of 958 patients with ARF
treated by any ventilator support (invasive or non-
invasive) for more than 6 hours and sequentially admit-
ted to the ICU [3], 518 patients were selected solely on
the basis of available blood samples (Figure 1). Their
clinical management followed standard practice in the
12 participating ICUs. Blood samples were taken within
6 hours of commencing ventilation on day (D) zero (D0)
(n = 487) and on D2 (n = 495), D7 (n = 323) and D21
(n = 62). Of 518 patients, only 47 had all four samples
drawn. This analysis, unless otherwise noted, utilized the
D0, D2 and D7 samples.
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Syndrome (ARDS) was diagnosed using the American-
European Consensus Conference criteria [20]. Mortality
was calculated from the beginning of the ARF. Of the
518 patients included in this study, 17 patients (3.3% of
patients) had ARDS and 27 patients (5.2% of patients)
had ALI at the beginning of ARF. The remainder, 474
patients, did not have ALI or ARDS at the beginning
of ARF.
Patient data
Patient data were grouped by APACHE III diagnostic
group [3]. Diagnostic groups are outlined in Table 1, and
patient selection is detailed in Figure 1. The presence of
chronic morbidities and risk factors preceding ARF,
Simplified Acute Physiology Score (SAPS) II [21] minus
oxygen points, day 1 Sequential Organ Failure Assess-
ment (SOFA) score [22] minus respiration points and
the APACHE III score [23] were recorded. Outcome
measures were mortality at 90 days and 12 months.
Normal range study
Healthy adult male and female patients (n = 138) in
the following age groups were recruited: 18 to 50 years
(n = 56), 51 to 65 years (n = 52) and over 66 years
(n = 30). Eligibility required body mass index (BMI)
of <30, no major hospitalization within the last 3 years, no
current acute illness or injury, no chronic inflammatory or
neoplastic disease and no medication for significant
clinical disease.
Following interview by the nurse coordinator, volun-
teers were formally consented by the study coordinator
(DJP) and completed a form outlining any pertinentTable 1 Diagnostic categories of patients
















Patients grouped on the basis of their diagnostic categories as defined
according to Acute Physiology and Chronic Health Evaluation (APACHE III)
diagnostic groups (3).medical details. The following data were stored and used
for statistical analyses: sex, age, ethnicity, weight, height,
BMI, hip and waist circumference, details of hospitaliza-
tions, allergies, tobacco and alcohol usage (approximate
number of standard alcoholic drinks (10 g alcohol or
equivalent] per week), details of any medications and, if
taking cholesterol-lowering medication, they were exclu-
ded from the study. Details of exercise (hours per week
of exercise beyond normal lifestyle activity), symptoms
potentially indicative of health problems (either past or
present) were recorded including the date of last men-
strual period (for premenopausal women). A sample of
120 mL of blood was taken from each volunteer, allowed
to clot and the serum from each sample was aliquoted
into smaller individual volumes and stored at -20°C to
enable normal ranges to be determined for new assays.
Immunoassays
Total serum activin A was measured by a two-site
ELISA [24] with a sensitivity of 7.7 pg/mL and intra-
and inter-assay coefficients of variation of 5.7% and
7.7%, respectively. Total serum activin B was measured
by ELISA as previously described [25] with no cross-
reactivity with inhibin B or activin A. The assay sensitiv-
ity is 0.019 ng/mL and the intra- and inter-assay coeffi-
cients of variation range between 2.7 to 6.2%, and 5.5 to
11.7%, respectively. Total follistatin was measured by
radioimmunoassay as previously published [26] with a
sensitivity of 1.44 ng/mL and intra- and inter-assay
coefficients of variation of 5.8% and 7.1%, respectively.
Statistical analysis
SPSS 21 (IBM, New York, NY USA), SPSS Modeler 14.2
(IBM), SAS 9.3 (SAS, New York, NY USA) and GraphPad
Prism 6 (GraphPad, La Jolla, Ca USA) were used to
analyze data. Analyses used were the Kruskal-Wallis test
with Dunn’s multiple comparison post-hoc test (all mul-
tiple comparison analyses), Mann-Whitney U-Test (nor-
mal range comparisons) and the Chi-squared test (for age
survival analysis). The predictive model was created using a
binary logistic regression. Validation was performed using
bootstrapping [27,28]. Hosmer-Lemeshow tests, area under
curve (AUC), positive likelihood ratio (LR) with 95% CIs, ac-
curacy with 95% CIs, net reclassification index (NRI) and
the integrated discrimination improvement index (IDI) were
calculated [29]. Survival evaluation used a log-rank test. Data
are reported as mean ± standard error of the mean (SEM)
and 95% CI, with a P-value less than 0.05 considered statisti-
cally significant. Exact statistics are reported.
For the purposes of the predictive model, although
substantially more accurate models were possible, they
were unlikely to be generalizable, contained too many
terms or would be difficult to perform at multiple time
points. The threshold was set at 0.5, as we would
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Serum Activin A concentrations were 0.11 ± 0.41 ng/mL
(range 0.036 to 0.283 ng/mL) and significantly increased
with age, regardless of gender (r2 = 0.25, P <0.0001).
Multivariate analysis showed a significant contribution
of ethnicity (P = 0.011). Although potential participants
were excluded if they were taking cholesterol-lowering
medications, a proportion of participants were taking
other medications. There were no significant effects of
weight, hip circumference, alcohol consumption, smok-
ing, time since hospitalization, exercise, allergies, or days
since last menstruation. There were minor correlations
with height (r2 = 0.031, P = 0.039), BMI (r2 = 0.028,
P = 0.048) and waist circumference (r2 = 0.03, P = 0.042;
Additional file 1: Figure E1). Activin A concentrations for
each age group of 18 to 50 years, 51 to 65 years and
66+ years are shown in Table 2 and Figure 2.
Activin B
Serum activin B concentrations were 0.070 ± 0.002 ng/mL
(range 0.020 to 0.156 ng/mL). There were no significant
differences with ethnicity and hypertensive medications.
Age and sex were significantly correlated with activin B
levels (P = 0.002). In female patients, activin B concentra-
tions decreased with age, whereas in male patients they
increased with age. Data for male and female patients
appear separately in Table 2, and additional data are
shown in Figure 2. These data have been publishedTable 2 Normal ranges for serum activin A, B and
follistatin




18 to 50 56 0.087 ± 0.004 0.080, 0.095
51 to 65 52 0.110 ± 0.005 0.099, 0.120
66+ 30 0.150 ± 0.009 0.130, 0.170
Activin B F
18 to 50 29 0.085 ± 0.005 0.074, 0.096
51 to 65 31 0.062 ± 0.005 0.051, 0.073
66+ 20 0.071 ± 0.005 0.060, 0.082
Activin B M
18 to 50 27 0.061 ± 0.004 0.053, 0.069
51 to 65 21 0.064 ± 0.005 0.053, 0.074
66+ 10 0.086 ± 0.008 0.069, 0.100
Follistatin M/F
18 to 50 56 11.67 ± 0.63 10.40, 12.94
51 to 65 52 12.61 ± 0.58 11.44, 13.78
66+ 30 14.36 ± 0.71 12.90, 15.82
Reference ranges for activin A, activin B and follistatin, presented as mean ±
standard error of the mean concentrations and 95% CI M, male; F, female.previously as part of the validation of the activin B assay
[25] but are included in this paper to assist the reader in
evaluating the use of this parameter in the management of
patients with ARF.
Follistatin
Serum follistatin concentrations were 12.61 ± 0.38 ng/mL
(range 3.67 to 25.42 ng/mL). There were no significant
correlations with sex, ethnicity, waist or hip circumfer-
ence, or BMI. Serum follistatin levels correlated with the
number of days since the last menstrual period (r2 = 0.29,
P = 0.004). Follistatin concentrations were positively
correlated with age (P = 0.004). Data for each age range
are shown in Table 2 and Figure 2.
Association of activins A and B, and follistatin, and
survival at 12 months
This study used samples from a subset of patients from
the FINNALI study [3]. The subset of patients included
in this study were significantly less likely to die, stayed
about a day longer in ICU and were less likely to be an
emergency admission compared to the original FINNALI
study (Additional file 1: Table E1).
Activin A levels
Sample D0 (within 6 hours from the commencement
of ventilation) activin A levels did not differ between
male and female patients and were markedly elevated
(P <0.0001) above the normal range in all diagnostic
groups (Figure 3, Additional file 1: Table E6) other
than in the non-operative/postoperative trauma (group 9)
and the postoperative respiratory, gynecology, renal and
orthopedic groups (group 10).
Serum activin A levels measured at D0 in patients
who died at 90 days and 12 months were also markedly
elevated above normal (P <0.0001). There were no sig-
nificant differences between patients who survived and
those who had died at those time points (Additional file
1: Table E1). In contrast, at the D2 time point (two days
after the commencement of ventilation) serum activin A
levels were significantly different between those who
were alive and those who died at 90 days (P = 0.008)
and 12 months (P = 0.0003; Additional file 1: Table E2).
However, at the D7 sample time point, there were no
differences. The rate of change between samples D0, D2
and D7 did not differ between those who lived and those
who had died.
Activin B levels
In sample D0 serum activin B concentrations did not
differ significantly between the sexes and were markedly
elevated above the normal range in groups 1 to 6
and group 8 (groups 1 to 5, and 8, P <0.0001; group 6,
P = 0.025) but were not significantly elevated in non-
Figure 2 Reference ranges from normal subjects, depicted as (A) activin A (ng/mL), (B) activin B (ng/mL), (C) follistatin (ng/mL),
(D) activin A to activin B ratio, (E) activin A to follistatin ratio, and (F) activin B to follistatin ratio. In each panel, n = number of subjects.
SEM, standard error of the mean; Min, minimum; Max, maximum; 95% CI, 95% confidence interval; 5-95%, 5 to 95% values.
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tive/postoperative trauma (Group 9), and the postopera-
tive respiratory, gynecology, renal and orthopedic group
(group 10, Figure 3 and Additional file 1: Table E6). In D0
samples, activin B levels were elevated (P <0.0001) above
reference levels, but did not differ between those who
survived and who had died at 90 days, or at 12 months
(Additional file 1: Table E2). For both the D2 and D7 sam-
ples, serum activin B levels were significantly higher in
those who died at 90 days and 12 months compared with
those surviving at those times (Additional file 1: Table E2).Follistatin levels
In the D0 sample, follistatin levels did not differ between
the sexes and were elevated significantly above the
normal range in groups 1 (P <0.0001), 3 (P <0.0001), 4
(P = 0.024), and 5 (P = 0.008) (Figure 3 and Additional
file 1: Table E6). Using sample D0, patients had signifi-
cantly (P = 0.0004) higher follistatin levels compared to
the normal range, but there were no differences between
those who were dead or alive at 90 days, or at 12 months
(Additional file 1: Table E2). In the D2 samples,
serum follistatin levels were higher than the reference
Figure 3 Activin A/B and follistatin concentrations in ARF patients at day zero (D0) or day 2 (D2), compared with reference group
levels (reference data). Each patient group was sorted by diagnosis (DG Group). Differing letters (a or b) denote a significant difference from the
reference data. (NO) non-operative and (PO) Post-operative.
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12 months (P = 0.0018). Among those surviving to 90
days and 12 months, serum follistatin levels were
lower than the normal range cohort (P = 0.008 and
P = 0.033, respectively) for the D7 time point only.Serum follistatin levels in samples D2 and D7 samples
were higher in those who had died at 90 days and at
12 months compared with those who lived, except for
death at 12 months in the D2 sample (Additional file
1: Table E2).
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We also evaluated the effect of having ALI or ARDS on
the levels of activins and follistatin. Of the 518 patients
included in this study, we had data on ALI/ARDS for
495 patients. Of those 495 patients, 27 had ALI and 17
had ARDS. Patients with ALI did have statistically
significantly higher levels of serum activin A at time
points D2 (P = 0.04) and D7 (P = 0.01), but not at D0,
when compared to patients without ALI. There were no
differences in activin B or follistatin levels for patients
with ALI compared with patients without ALI. When
comparing patients with ALI who were alive and those
who died at 90 days and 12 months, no differences in
serum activins and follistatin levels were found at any
time point.
Comparing ARDS patients with patients without ARDS,
no differences were detected in serum activins or follista-
tin at any time point examined. Comparing ARDS patients
who lived and died at 90 days and 12 months, no differ-
ences in serum activins and follistatin levels were found at
any time point.
Survival
Gender did not affect survival at any time point. Age
significantly increased the probability of death at 90 days
and 12 months, using logistic regression (90 days
(odds ratio (OR) per year 1.034, 95% CI 1.019, 1.049;
P <0.00001), 12 months (OR per year 1.034, 95% CI
1.021, 1.048; P <0.00001). When evaluating survival
using three groups, patients aged 16 to 50, 51 to 65
and 65+ years, patients who were over 65 years of age had
2.6 times greater risk of death at 12 months compared
with patients who were 16 to 50 years of age (P = 0.0002),
and patients aged 65+ had 1.87 times greater risk of death
than those aged 51 to 65 years old (P = 0.0067), but there
was no difference between those aged 16 to 50 and those
aged 51 to 65 years ( P = 0.11). At 90 days, patients who
were aged over 65 years had 3.1 times greater risk of death
compared to patients aged 16 to 50 years (P <0.0001),
patients aged 65+ had 1.9 times greater risk of death than
those aged 51 to 65 years old (P = 0.0043), there was no
effect between those aged 16 to 50 and those aged 51 to
65 years ( P = 0.26).
Predictive model
In order to formulate a scoring system that would facili-
tate the use of measures of the activins and follistatin by
clinicians, we assessed a variety of models to determine
their value in predicting patient outcome. We utilized
MDLP (minimal description length principle) optimal
scaling, maximum, mean and upper/lower 95% CI of the
normal range to determine if activin A/B and follistatin
levels would provide useful adjuncts to existing scoring
systems in predicting survival.For D0 samples, concentrations above the reference
maximum, or any other metric for activin A, activin B
and follistatin, were not useful in predicting outcome at
90 days or at 12 months. For D2 Samples, activin A and
B offered good performance in predicting outcome at 90
days and 12 months, using the reference maximum as
the cutoff point (Additional file 1: Table E3). Follistatin
did not offer useful predictions using any metric.
Although D7 samples offered good predictive value, we
elected not to use them for modeling. A sample drawn
at 7 days after the commencement of ventilation is not a
practical time point for clinical use. Further, the use of
multiple activins/follistatin measurements at multiple
time points was not considered practical.
Based on these results, we used sample D2 for predict-
ing ICU survival. We therefore used a constructed variable
for activin A and B at time-point D2 with a three-option
design, to evaluate specifically: when neither activin A or
B were above the reference maximum; when either activin
A or B were above the reference maximum, or when both
activin A and B were above the reference maximum. This
approach gave a good separation for survival curves, and
was a good starting point for modeling (Figure 4). These
constructed variables were robust using the AUC, positive
LR, relative risk and observed risk measures (Additional
file 1: Table E4).
We then developed a scoring system, the follistatin,
and activin A and B (FAB) score to predict the risk of
death over the year after the initiation of ventilation.
Details of the components incorporated into the score
are given in the legend to Table 3; as well as measures of
activins A, and B, the score utilizes several standard
criteria routinely collected in the management of
critically ill patients in the ICU. This is a balanced
score, calibrated at both 90 days (Hosmer-Lemeshow
test, Chi-square = 9.502, P = 0.302) and 12 months
(Chi- square = 12.222, P = 0.142).
Comparing the FAB score without the activin A/B
component with the complete FAB score demonstrated
that the addition of the activin A/B component substan-
tially improved the predictive value of the model for
outcomes at both 90 days and 12 months.
For 90 days, the addition of the activin A/B component
yielded a categorical NRI of 0.0058 (95% CI -0.0565,
0.0682; P = 0.854), a category-free NRI of 0.4444 (95% CI
0.2375, 0.6513; P = 0.00001), and an IDI of 0.0268 (95% CI
0.008, 0.0457; P = 0.0053). For 12 months, the addition of
the activin A/B component yielded a categorical NRI of
0.0414 (95% CI: -0.0205, 0.1032; P = 0.190), a category-
free NRI of 0.4942 (95% CI 0.2997, 0.6887; P <0.000001)
and an IDI of 0.0322 (95% CI 0.015, 0.0495; P = 0.00025).
To better stratify risk, the FAB score for purposes of
this analysis was divided from 0.0 to 1.0 in 10 equal bins
(each 0.1 wide), with the top value included in the lower
Figure 4 Patient survival curves of up to 12 months according
to activins A/B in the day 2 (D2) sample. Solid line: when neither
activin A or activin B were over the reference maximum; dashed
line: when either activin A or activin B were over the reference
maximum (dashed line); dotted line: when both activin A and activin
B were over the reference maximum. Statistically, comparing neither
activin A or B over the reference maximum to either activin A or B
over the reference maximum yielded P = 0.0003; comparing neither
activin A or B over the reference maximum to both activin A or B
over the reference maximum yielded P <0.0001, and comparing
either activin A or B over the reference maximum to both activin A
and B over over the reference maximum yielded P = 0.009.










of ventilation – FAB
Constructed variable
Choice Activin A <0.283 ng/mL 0
Activin B <0.156 ng/mL
Activin A >0.283 ng/mL OR 0.934
Activin B >0.156 ng/mL
Activin A >0.283 ng/mL AND 1.197





























SOFA maximal score Numeric 0.220
Constant −7.765
FAB, follistatin, and activin A and B; SOFA: Sequential Organ Failure
Assessment. Formula for FAB score: (Age*0.041) + (Activin A/B component) +
(Presence of xhronic restrictive pulmonary disease) + (Presence of chronic
obstructive pulmonary disease) + (Diagnostic group) + (Maximal SOFA
score*0.220) + Constant. This produces a range with a mean of zero. To obtain
the risk profile, each value was entered into the following equation:
Probability Estimate ¼ lnResult1þ lnResult .
This produced a range of values from 0.0 to 1.0, a score approaching 1.0
having the greatest risk of death and approaching 0.0 having the least risk of
death. For risk stratification purposes, it was then divided into 10 bins, each
0.1 wide with the upper endpoint of each bin included in the lower bin.
The equation factor listed is the value that should be inserted into
the equation.
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shown in Additional file 1: Table E5.
Use of this predictive model in the individual diagnostic
groups
The use of this predictive model in the individual diag-
nostic groups was not equally predictive in each group.
As is evident in Figure 3, not all the diagnostic groups
had levels of activin A and B above the reference mean
or reference maximum and hence in our predictive
model the diagnostic group is used to account for differ-
ences in the relative mortality risk in each group. Using
the FAB score and applying it to each diagnostic group
individually demonstrates that it performed well, statisti-
cally significantly above the null hypothesis area of 0.5 for
on the receiver operating characteristic (ROC) curve, in
all but three of the groups (Additional file 1: Table E7).
This is primarily due to the lower numbers in groups 4, 9
and 10. Another factor is that the outcomes can be remote
from the causative factor for the ARF and that some
groups are heterogeneous.
Discussion
This paper provides a unique dataset on serum levels of
activin A and B, and follistatin in critically ill patients,
had ARF, and were in the ICU. These data, with the
establishment of normal ranges for the assays based on
substantive numbers of healthy volunteers, enable a
critical appraisal of the value of these measurements fordiagnostic and predictive purposes. The findings of this
study establish that the concentrations of both activin A
and B are substantially increased in most of the diagnos-
tic groups of critically ill patients with ARF. This is in
keeping with the demonstration that activin A is a key
regulator of the inflammatory response induced by LPS
[11] and the small study that indicated that there were
Figure 5 Survival curves by FAB score (binned). FAB Scores closer to 0.0 have the lowest risk of death, and those closest to 1.0 have the
greatest risk of death. FAB, follistatin, and activin A and B.
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cemia [9].
In addition, the present study demonstrates that serum
activin B levels were substantially elevated in a large pro-
portion of this critically ill cohort. Further, having activin
B levels above the reference maximum (combined with
other factors) gives the best predictor of mortality subse-
quent to admission. This finding is of interest, given that
although clear data in mice and humans indicate that
activin A is a major controller of the inflammatory
response [9,11,30], very little is known about the role of
activin B in inflammation and fibrosis.
The advantages of measuring activin A and B are that
an elevated measurement of these proteins (A and/or B)
at 2 days after the initiation of ventilation, still has pre-
dictive power at 12 months after admission to the ICU.
Adding the activin A and B measurements improves
upon the already robust base model (Table 3), as shown
by the significant NRI and IDI results, and therefore
identifies patients who are currently not detected as
being of higher mortality risk.
Activin A stimulates macrophages to produce nitric
oxide [31], and increasing activin A levels results in
apoptosis of hepatocytes and B lymphocytes, resulting in
liver failure and suppression of immunological respon-
ses, both of which can cause death [32,33]. Further,
activin A stimulates fibroblast mitosis in vitro andin vivo, as well as expression of metallo-matrix proteases
in macrophages after experimental induction of myocar-
dial infarction [34-36]. The latter is consistent with the
elevated activin A levels in group 3 consisting of patients
with non-operative cardiovascular conditions associated
with ARF, and with Ynestad and colleagues [36], who
noted that the magnitude of the increase in activin A
levels paralleled the increasing severity of the cardiac
failure. In this group, activin B levels were also elevated,
again providing a novel finding, the pathophysiological
basis of which is unknown. Apart from the capacity for
activin B as well as activin A to cause apoptosis of
MPC-11 cells, there is a paucity of data concerning its
actions [37] other than experiments wherein substitution
of the βB subunit for βA in mice suggested that the βB
subunit acted as a partial agonist when compared to the
βA subunit [38].
This large patient cohort adds substantially to the
available data in humans and further supports the
concept that activin A, and now activin B, are valuable
markers of inflammatory responses. We recognize that
this paper provides data from a study performed some
time ago. A new prospective study is now required that
builds in the analysis of the activins and follistatin in the
management of patients with ARF in the ICU.
The importance of activin A as a major regulator of
the inflammatory response is supported by its capacity
de Kretser et al. Critical Care 2013, 17:R263 Page 10 of 13
http://ccforum.com/content/17/5/R263to stimulate monocytes/macrophages to produce a
number of inflammatory mediators including IL1β, TNFα,
IL6, nitric oxide, prostaglandin E2 and thromboxane
[39-41]. Further, studies in mouse models and human
data clearly establish a role for this protein in inflamma-
tory bowel disease, rheumatoid arthritis, allergy-induced
asthma and wound healing [14,42-45]. Further, studies
following the progress of patients with multiple forms of
inflammatory diseases using the activins and follistatin as
markers would establish the value of using the levels of
both activins A and B as markers of organ function in
inflammation.
There may be multiple factors linking these proteins
to survival and these are summarized in Figure 6. In
acute experiments that used a lethal LPS challenge in
mice, those with the highest activin A levels had the
greatest mortality [11]. Proof that these elevated activin A
levels caused death emerged from halving the LPS-
induced mortality by the administration of follistatin,
which binds activin A virtually irreversibly and targets the
complex to a lysosomal degradation pathway [12,13,46].
Although not formally addressed, the rapid action of fol-
listatin in halving the LPS-induced mortality, usually
within 24 hours, may result from blocking the rapid
increase in nitric oxide arising from the stimulation of
macrophages by activin A, causing hypotension [31].
However, the longer-term impact on survival and its pre-
diction by the measurement of activins A and B are likely
to be related to the capacity of elevated levels of activin A
to cause apoptosis of hepatocytes, decreasing liver func-
tion and compromising immunological defense mecha-
nisms resulting from the apoptosis of B lymphocytes. In
addition, elevated activin A levels drive fibrosis and thisFigure 6 Diagrammatic summary of the actions of the activins
as they pertain to the lung. These proteins are produced in
neutrophils, macrophages, fibroblasts, the endothelium and the
bronchial epithelium, as well as multiple sites in other tissues, details of
which are found in the review by Hedger et al. [9]. (NO) Nitric oxide.may lead to limitation of pulmonary, hepatic and renal
function [9,34,41,44]. Further, elevated activin A levels can
cause cachexia resulting from activin A signaling through
type II and type I receptors [47]. This pathway, shared by
myostatin, leads to the stimulation of the Smad2/3/4 path-
way resulting in the dephosphorylation of the transcrip-
tion factor foxo3a and leading to its nuclear retention
[48]. The increased levels of nuclear foxo3a induce the
expression of muscle specific ubiquitin ligases, MuRF-1
and Atrogin-1, which stimulate the degradation of myo-
fibrillar proteins such as myosin, resulting in marked
muscle wasting [49]. Although a role for activin B in
cachexia is yet to be established, activin B can act
through the same signaling pathway via Smad 2/3/4
and also can activate the pathway via ALK7, another
type 1 receptor [50].
Defining the pathways through which high activin A
levels cause death is of critical importance as therapeutic
options will become available using follistatin, which has
the capacity to bind and neutralize the actions of both
activin A and B. Further, the development of soluble
activin receptor blockers offer alternative possibilities for
more selective treatment as follistatin also inhibits the
actions of several of the bone morphogenetic proteins,
growth and differentiation factor (GDF) 8 (myostatin),
GDF9, and TGFβ3 [9].
In this context, it was surprising that the activin to
follistatin ratio did not correlate with long-term survival
and it was clear that concentrations of follistatin were
higher in those patients who died than those who
survived, at D7. In part, this probably results from the
increased levels of activin A and B, measured in these
severely ill patients, to stimulate follistatin levels.Conclusions
This study establishes that activins A and B, novel mod-
ulators of inflammation and fibrosis, are elevated in a
large number of patients with ARF in the ICU. It also
demonstrates the value of measuring their levels in the
management of critically ill patients in intensive care, as
patients with elevated levels of both activins above the
normal range are more likely to die at 3 and 12 months
after their admission to the ICU with ARF. These higher
mortality rates are the likely result of the ability of in-
creased levels of activin A to cause inflammation and
the production of nitric oxide, and induce apoptosis of
hepatocytes and B lymphocytes. Further, as activin A
also induces fibrosis in multiple tissues, such as the lung,
liver and kidney, it has the capacity to cause sub-optimal
organ function, thereby contributing to poor survival
[8,11,41]. These data should stimulate the development
of inhibitors of the action of the activins such as follista-
tin as therapeutic agents.
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 ARF, particularly in the ICU, results in significant
mortality. Novel biomarkers are needed to predict
patient outcomes and guide potential future
therapies.
 We demonstrated that the novel modulators of
inflammation and fibrosis, activins A, B and
follistatin, are elevated in the majority of patients
with ARF and marked increases are linked to
poor outcomes.
 The severity of the increases in serum levels of
activins A and B can assist in the prediction of
the outcomes in ARF and helps to identify those
patients at greatest risk of death, thereby
establishing the basis for the development of new
therapeutic agents targeted at modulating the
bioactivity of these protein biomarkers.Additional file
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